Glatiramer Acetate: Conforms to the Original
Russian Biotechnological Company BIOCAD authorized a generic drug glatiramer acetate. Now a generic version of Copaxon (glatiramer acetate) for treatment of multiple sclerosis manufactured by Israeli Teva will be available in Russia. According to official statistical data, this disorder affects over 70 thousand persons in Russia. However, as estimated by experts, the real incidence may be twice as more.
The development of Russian generic of glatiramer acetate has been ongoing for four years. A two year study proving equivalence of the drug to the reference drug for efficacy and safety. The fact of approval of generic drug glatiramer acetate is important to provide national safety. Besides, BIOCAD performs full cycle manufacture including synthesis of substance, providing independence from suppliers and guarantees high quality.
The price of approved generic version of glatiramer acetate will be 30% lower than the price of the original drug. Government costs for purchase within the 7 Nosologies program will be lower, and first line drugs will be more affordable.